Possibia

1697410

Last Update Posted: 2014-12-30

Recruiting status is unknown

All Genders

accepted

16 Years +

1000 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Continuos Terlipressin Infusion in Septic Shock

The purpose of this study is to evaluate the efficacy of terlipressin for treating septic shock.

Septic shock is the most common cause of death in intensive care units and has a mortality rate of 40 to 60%.Vasopressin is commonly used as an adjunct to catecholamines to support blood pressure in refractory septic shock.Recently small sample clinical study suggest that Terlipressin,a vasopressin analogues, was effective in reversing sepsis-induced arterial hypotension and in reducing norepinephrine requirements.But its effect on mortality is unknown.Invesgators hypothesized that Terlipressin as compared with norepinephrine would decrease mortality among patients with septic shock.

Eligibility

Relevant conditions:

Septic Shock

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Data sourced from ClinicalTrials.gov